This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Alzheimer's Disease Psychosis

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Sponsored by ACADIA Pharmaceuticals Inc.

About this trial

Last updated 7 months ago

Study ID

ACP-204-008

Status

Enrolling by invitation

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
55 to 95 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started a year ago

What is this trial about?

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

What are the participation requirements?

Yes

Inclusion Criteria

- Subject has successfully completed ACP-204-006 study - Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential - Subject has a designated study partner/caregiver - Subjects are able to complete all study visits with a study partner/caregiver - Signed inform consent form with a caregiver or legal representative

No

Exclusion Criteria

- Requires treatment with a medication prohibited by the protocol - Is in hospice and receiving end-of-life palliative care, or has become bedridden - Female who is pregnant or breastfeeding - Unstable clinically significant medical condition other than AD - Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.